Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours.

[1]  D. Milne,et al.  Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death‐1 monoclonal antibodies for advanced melanoma , 2017, Asia-Pacific journal of clinical oncology.

[2]  V. Servois,et al.  Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Razelle Kurzrock,et al.  Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate , 2017, Clinical Cancer Research.

[4]  T. Seiwert,et al.  Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Schadendorf,et al.  Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Charles Ferté,et al.  Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 , 2016, Clinical Cancer Research.

[7]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[8]  Lajos Pusztai,et al.  Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Vicier,et al.  The development of immunotherapy in older adults: New treatments, new toxicities? , 2016, Journal of geriatric oncology.

[10]  J. Wolchok,et al.  Efficacy and safety of checkpoint blockade for treatment of advanced melanoma (mel) in patients (pts) age 80 and older (80 , 2016 .

[11]  P. Nicolas,et al.  Is there a clinical benefit of anti-PD-1 in patients older than 75 years with previously treated solid tumour? , 2016 .

[12]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[13]  S. Moschos,et al.  Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. , 2016, Cancer treatment reviews.

[14]  P. Chanson,et al.  Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[16]  J. Weber,et al.  Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanoma , 2015, Journal of Immunotherapy for Cancer.

[17]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[18]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[19]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[20]  F. Cappuzzo,et al.  Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.

[21]  P. Ascierto,et al.  Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme , 2014, Journal of experimental & clinical cancer research : CR.

[22]  W. Murphy,et al.  Impact of aging in cancer immunotherapy , 2013, Oncoimmunology.

[23]  L. Ferrucci,et al.  Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy , 2013, The Journal of experimental medicine.

[24]  Robert G. Nagele,et al.  Natural IgG Autoantibodies Are Abundant and Ubiquitous in Human Sera, and Their Number Is Influenced By Age, Gender, and Disease , 2013, PloS one.

[25]  O. Lesur,et al.  Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. , 2012, Seminars in immunology.

[26]  K. Scher,et al.  Under-representation of older adults in cancer registration trials: known problem, little progress. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[28]  L. Walker,et al.  The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses , 2011, Nature Reviews Immunology.

[29]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[30]  David Olmos,et al.  Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Quezada,et al.  Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy , 2008, Immunological reviews.

[32]  W. Kendal.  Dying with cancer , 2008, Cancer.

[33]  G. Pawelec,et al.  Immunological biomarkers of ageing in man: changes in both innate and adaptive immunity are associated with health and longevity , 2006, Biogerontology.

[34]  L. Siu,et al.  Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  I. Palomo,et al.  Immune System Dysfunction in the Elderly. , 2017, Anais da Academia Brasileira de Ciencias.

[36]  G. Pawelec,et al.  Immunology of aging and cancer development. , 2013, Interdisciplinary topics in gerontology.

[37]  C. Caruso,et al.  Prevalence of non organ-specific autoantibodies in healthy centenarians. , 2002, Archives of gerontology and geriatrics. Supplement.